3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Colorectal Neoplasms
19
Colonic Neoplasms
9
Pancreatic Neoplasms
8
Esophageal Neoplasms
7
Stomach Neoplasms
6
Rectal Neoplasms
5
Adenocarcinoma Of Esophagus
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Large B-Cell, Diffuse
4
Cholangiocarcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Endometrial Neoplasms
3
Adenocarcinoma
3
Recurrence
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Bowel Adenocarcinoma
1
Prostatic Neoplasms
1
Interventions
Cyclophosphamide
11
Rituximab
10
Prednisone
8
Lenalidomide
8
Vincristine
7
Doxorubicin
7
Bendamustine Hydrochloride
6
obinutuzumab
5
Magnetic Resonance Spectroscopy
4
fludarabine
3
Whole-Body Irradiation
3
Specimen Handling
3
R-CHOP protocol
3
Cyclosporine
3
Biopsy
3
zanubrutinib
2
fludarabine phosphate
2
Radiotherapy
2
Prednisolone
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Mycophenolic Acid
2
Melphalan
2
Gemcitabine
2
Etoposide
2
Cytarabine
2
venetoclax
1
umbralisib
1
treosulfan
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Oxaliplatin
×
30 days
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled